MedImmune Inks Exclusive License Agreement with La Jolla Institute for Asthma Discovery
March 04, 2009
MedImmune Inks Exclusive License Agreement with La Jolla Institute for Asthma Discovery
If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- UMMS Team Publishes In Vitro, In Vivo Data on Oral siRNA-Delivery Tech
April 30, 2009 / Gene Silencing News - UMich Spinout Lycera Nets $36M in VC Cash; Taps NYU Immunologist for New Research Program
April 22, 2009 / - MDRNA Narrows Pipeline to Focus Exclusively on Liver Cancer, Inks Licensing Deal with Novartis
March 26, 2009 / Gene Silencing News - RXi Names Inflammatory Disease as Lead Program; Neurological Disease Slips Off Radar
March 26, 2009 / Gene Silencing News - NKT Thera Closes $8M VC Round to Develop Rxs Based on NK Cell IP from Boston Institutions
March 18, 2009 /